Attovia raises US $90M in Series C with backing from Sanofi

USA – Biotech firm Attovia Therapeutics has raised US $90 million in Series C funding, with pharmaceutical giant Sanofi joining the round.

The funding brings Attovia’s total capital raised to US $255 million since its launch, reinforcing its position as a rising innovator in immunology and inflammatory (I&I) diseases.

The financing, led by Deep Track Capital, will support the development of Attovia’s unique class of biologics called ATTOBODIES — engineered biparatopic antibodies designed for high precision and strong binding to disease targets.

Attovia’s lead candidate, ATTO-1310, is being developed to treat chronic pruritus of unknown origin (CPUO), a debilitating condition characterized by severe itching without a known cause.

The drug, an anti–IL-31 antibody with an extended half-life, entered Phase I clinical trials in January.

“We now have a multi-year runway to advance our programs, grow our pipeline, and explore meaningful partnerships,” said Tao Fu, CEO of Attovia. “This gives us the flexibility to drive innovation forward.”

In addition to ATTO-1310, the funding will support ATTO-3712, a bispecific antibody designed to block both IL-13 and IL-31, key drivers of several inflammatory skin diseases.

This candidate is expected to enter clinical testing later this year. The company aims to address conditions like atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

The investment also fuels the expansion of Attovia’s broader ATTOBODY platform, including new multi-specific biologics targeted at inflammatory bowel disease (IBD) and other immune-mediated disorders.

The Series C drew strong interest from previous investors. Goldman Sachs Alternatives, which led Attovia’s US $105 million Series B in 2023, returned for this round.

Other backers include Vida Ventures, Mirae Asset Capital Life Science, venBio, Nextech Ventures, EcoR1 Capital, Illumina Ventures, Cormorant Asset Management, and Frazier Life Sciences — the latter having supported Attovia’s launch with US $60 million just two years ago.

Attovia’s growing appeal reflects a broader surge in biotech investment within the I&I space, particularly for bispecific and multi-specific antibodies, which are designed to target multiple disease pathways with a single therapy.

These novel drugs are gaining momentum due to their potential to improve treatment outcomes and reduce dosing frequency.